Caribou Biosciences Stock Performance
| CRBU Stock | USD 1.20 0.04 3.23% |
The firm shows a Beta (market volatility) of 0.41, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Caribou Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Caribou Biosciences is expected to be smaller as well. At this point, Caribou Biosciences has a negative expected return of -0.93%. Please make sure to confirm Caribou Biosciences' skewness, as well as the relationship between the day median price and relative strength index , to decide if Caribou Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Caribou Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | Acquisition by Whiting Nancy of 21500 shares of Caribou Biosciences at 6.12 subject to Rule 16b-3 | 12/24/2024 |
2 | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in ... | 01/07/2025 |
3 | Acquisition by Khan Ruhi Ahmad of 70000 shares of Caribou Biosciences subject to Rule 16b-3 | 01/17/2025 |
4 | DEADLINE ALERT Faruqi Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou ... | 01/22/2025 |
5 | ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. ... | 01/31/2025 |
6 | ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU | 02/11/2025 |
7 | CRBU INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Caribou Biosciences, ... | 02/13/2025 |
8 | Caribou Biosciences, Inc. Investors Please contact the Portnoy Law Firm to recover your losses. ... | 02/14/2025 |
9 | CRBU INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Ac... | 02/19/2025 |
10 | Acquisition by Braunstein Scott of 40500 shares of Caribou Biosciences at 1.41 subject to Rule 16b-3 | 02/20/2025 |
11 | Caribou Biosciences, Inc. is a favorite amongst institutional investors who own 62 | 02/25/2025 |
| Begin Period Cash Flow | 58.4 M |
Caribou |
Caribou Biosciences Relative Risk vs. Return Landscape
If you would invest 219.00 in Caribou Biosciences on November 28, 2024 and sell it today you would lose (99.00) from holding Caribou Biosciences or give up 45.21% of portfolio value over 90 days. Caribou Biosciences is currently does not generate positive expected returns and assumes 4.1035% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Caribou, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Caribou Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Caribou Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Caribou Biosciences, and traders can use it to determine the average amount a Caribou Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2271
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRBU |
Estimated Market Risk
| 4.1 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.93 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Caribou Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Caribou Biosciences by adding Caribou Biosciences to a well-diversified portfolio.
Caribou Biosciences Fundamentals Growth
Caribou Stock prices reflect investors' perceptions of the future prospects and financial health of Caribou Biosciences, and Caribou Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Caribou Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (16.67) % | ||||
| Current Valuation | (88.8 M) | ||||
| Shares Outstanding | 90.55 M | ||||
| Price To Book | 0.40 X | ||||
| Price To Sales | 9.79 X | ||||
| Revenue | 34.48 M | ||||
| Gross Profit | (119.49 M) | ||||
| EBITDA | (112.53 M) | ||||
| Net Income | (102.07 M) | ||||
| Cash And Equivalents | 339.92 M | ||||
| Cash Per Share | 5.59 X | ||||
| Total Debt | 27.11 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.23 X | ||||
| Book Value Per Share | 3.10 X | ||||
| Cash Flow From Operations | (93.29 M) | ||||
| Earnings Per Share | (1.66) X | ||||
| Market Capitalization | 112.29 M | ||||
| Total Asset | 432.21 M | ||||
| Retained Earnings | (299.29 M) | ||||
| Working Capital | 310.54 M | ||||
About Caribou Biosciences Performance
Assessing Caribou Biosciences' fundamental ratios provides investors with valuable insights into Caribou Biosciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Caribou Biosciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -7.2 K | -7.6 K | |
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.25) | (0.26) |
Things to note about Caribou Biosciences performance evaluation
Checking the ongoing alerts about Caribou Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Caribou Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Caribou Biosciences generated a negative expected return over the last 90 days | |
| Caribou Biosciences may become a speculative penny stock | |
| Caribou Biosciences has high historical volatility and very poor performance | |
| Caribou Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 34.48 M. Net Loss for the year was (102.07 M) with loss before overhead, payroll, taxes, and interest of (119.49 M). | |
| Caribou Biosciences currently holds about 339.92 M in cash with (93.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Caribou Biosciences, Inc. is a favorite amongst institutional investors who own 62 |
- Analyzing Caribou Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Caribou Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Caribou Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Caribou Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Caribou Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Caribou Biosciences' stock. These opinions can provide insight into Caribou Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.